

### Amendments to the Specification

Please replace the paragraph beginning at p. 13, line 25 ("Fig. 11 illustrates . . . ") with the following amended paragraph:

--Fig. 11A-B illustrate[[s]] the improvement in contralateral performance in animals treated with certain preferred dexamabinol derivatives as assessed in the Staircase test.--

Please replace the paragraph beginning at p. 13, line 31 ("Fig. 14 shows . . . ") with the following amended paragraph:

--Fig. 14A-D show[[s]] the effect of certain preferred dexamabinol derivative on tolerance toward morphine.--

Please replace TABLE 2 with the following amended TABLE 2:

**-- Table 2. ACTIVITIES OF PRS-211 COMPOUNDS.**

PRS number	NMDA BINDING IC50 (μM)	PGE2 % inhibition (at 10μM)	TNFα % inhibition (at 10μM)	NOS % inhibition (at 10μM)	Ear Edema ED50 (μmol/kg) [[C]] <u>CO</u>
211,006-000	8	41	46	19	104
211,007-000 HU-211	10	54	33	20	25
211,041-000	6	56	23	72	39
211,044-000	6	24	0		
211,047-000	100	28	0		
211,092-000	>50	57	22	86	28
211,095-000	2.5	72	11	34	29
211,102-000	2.5				

211,103-000	3				
211,118-000	32				
211,119-000	62	14		0	
211,128-000	>20	84	48	27	23
211,132-000	4.5	61	21	40	70
211,133-000	> 100				
211,134-000	> 100				
211,145-000	13	63	15	60	
211,159-000	>20	87	33	27	
211,204-000	10	83	28	85	34
211,211-000	4.6	83	18	0	
211,212-000	7.5	96	14	0	
211,220-000	0.35	59	11	24	57
211,251-000	>100	91	0	37	
211,253-000	>100	92	0	27	
211,255-000	>100	94	0	7	
211,257-000	>100	88	10	39	

--